Physician

Christian Anton Thomas, MD

According to 2025 Medicare claims, Christian Thomas, MD (NPI: 1487651584) practices hematology/oncology in the Portland-South Portland, ME market, with the plurality of this provider's patient population coming from Cumberland, ME. This provider's primary affiliated billing organization is MAINE CENTER FOR CANCER MEDICINE & BLOOD DISORDERS, P.A. (NPI: 1205896107; TIN: 010357684) and primary practice location at 04092-4877. Thomas is affiliated with the MaineHealth Accountable Care Organization (ACO ID: A1290), participating under the MSSP model.

Thomas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 492 traditional Medicare patients, billed 154,747 HCPCS/CPT codes, and received $3,185,668 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,379 prescription claims across 284 beneficiaries totaling $12,770,902 in drug costs, led by Nubeqa (Darolutamide). 2020 DME data shows 19 claims. Open Payments data shows 44 records totaling $714,738. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $817,486 to $12,770,902. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	469	168,104	$1,867,346
2016	508	126,065	$2,093,510
2017	498	113,616	$2,596,189
2018	507	158,107	$3,394,623
2019	537	160,725	$3,810,146
2020	468	126,140	$2,755,467
2021	572	164,085	$2,924,421
2022	550	151,769	$3,183,393
2023	508	143,746	$2,806,840
2024	492	154,747	$3,185,668

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	145	949	$817,486
2016	178	1,068	$1,694,717
2017	211	1,639	$3,431,867
2018	223	1,646	$4,271,875
2019	231	1,698	$4,868,214
2020	223	1,523	$5,341,157
2021	202	1,655	$6,724,911
2022	207	1,726	$8,816,099
2023	274	2,233	$10,825,750
2024	284	2,379	$12,770,902

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	15	$299
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	19	$1,309
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	145	336	$146
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	245	745	$100
80053	Blood test, comprehensive group of blood chemicals	377	1,294	$10
36415	Insertion of needle into vein for collection of blood sample	340	1,179	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	383	1,308	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Nubeqa	Darolutamide	234	7,140	$3,168,457
Erleada	Apalutamide	146	4,650	$2,108,826
Xtandi	Enzalutamide	116	3,480	$1,604,326
Cabometyx	Cabozantinib S-Malate	69	2,048	$1,586,893
Abiraterone Acetate	Abiraterone Acetate	454	13,860	$1,137,506

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$124	EMD Serono, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	39	$714,614	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christian Anton Thomas, MD?

Tedicare shows public-source Medicare data for Christian Anton Thomas, MD (NPI 1487651584), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christian Anton Thomas, MD have ACO affiliation data?

Christian Anton Thomas, MD is shown with ACO affiliation data for MaineHealth Accountable Care Organization (MSSP, ACO ID A1290).

What billing organization is linked to Christian Anton Thomas, MD?

Christian Anton Thomas, MD is linked to MAINE CENTER FOR CANCER MEDICINE & BLOOD DISORDERS, P.A. (billing NPI 1205896107) in the available physician profile data.

Does Christian Anton Thomas, MD have Open Payments data?

Christian Anton Thomas, MD has 44 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.